Apolipoprotein E phenotypes in controls and hypertensive patients with and without gallstones
| Controls | Hypertensive patients | All | ||||||
|---|---|---|---|---|---|---|---|---|
| Phenotype | GSD n (%) | No GSD n (%) | GSD n (%) | No GSD n (%) | GSD n (%) | No GSD n (%) | ||
| Women | ||||||||
| E 2/2 | 0 (0) | 1 (0.5) | 0 (0) | 3 (1.5) | 0 (0) | 4 (0.9) | ||
| E 2/3 | 2 (4.3) | 23 (10.5) | 1 (1.9) | 10 (4.9) | 3 (3.0) | 33 (7.8) | ||
| E 2/4 | 0 (0) | 2 (0.9) | 0 (0) | 3 (1.5) | 0 (0) | 5 (1.2) | ||
| E 3/3 | 2 (55.3) | 123 (55.9) | 38 (70.4) | 119 (58.6) | 64 (63.4) | 242 (57.2) | ||
| E 4/3 | 18 (38.3) | 67 (30.5) | 14 (25.9) | 59 (29.1) | 32 (31.7) | 126 (29.8) | ||
| E 4/4 | 1 (2.1) | 4 (1.8) | 1 (1.9) | 9 (4.4) | 2 (2.0) | 13 (3.1) | ||
| All | 47 | 220 | 54 | 203 | 101 | 423 | ||
| Men | ||||||||
| E 2/2 | 0 (0) | 1 (0.4) | 0 (0) | 1 (0.4) | 0 (0) | 2 (0.4) | ||
| E 2/3 | 0 (0) | 12 (5.0) | 2 (6.7) | 9 (3.9) | 2 (4.3) | 21 (4.4) | ||
| E 2/4 | 1 (5.9) | 4 (1.7) | 0 (0) | 4 (1.7) | 1 (2.1) | 8 (1.7) | ||
| E 3/3 | 9 (52.9) | 143 (59.1) | 16 (53.3) | 145 (62.8) | 25 (53.2) | 288 (60.9) | ||
| E 4/3 | 6 (35.3) | 72 (29.8) | 12 (40.0) | 66 (28.6) | 18 (38.3) | 138 (29.2) | ||
| E 4/4 | 1 (5.9) | 10 (4.1) | 0 (0) | 6 (2.6) | 1 (2.1) | 16 (3.4) | ||
| All | 17 | 242 | 30 | 231 | 47 | 473 | ||